Kevzara Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Kevzara market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to factors such as increased support from healthcare providers and treatment guidelines, a rising focus on personalized medicine, greater healthcare awareness and early diagnosis, successful approvals and clinical trials, and advancements in biologic therapies.

The projected growth in the forecast period is driven by factors such as the increasing prevalence of rheumatoid arthritis, higher demand for immunomodulators, improvements in healthcare infrastructure, a growing aging population, and heightened health consciousness. Key trends expected in the forecast period include advancements in biotechnological and pharmaceutical research, progress in monoclonal antibody technology, continued regulatory support, innovations in drug delivery methods, and an expanded emphasis on personalized medicine.

The growing prevalence of rheumatoid arthritis (RA) is expected to significantly drive the growth of the kevzara market in the coming years. Rheumatoid arthritis is a chronic autoimmune disorder that primarily affects the joints, leading to inflammation, pain, swelling, and stiffness. Factors such as genetic predisposition, environmental triggers, hormonal influences, and immune system dysfunction contribute to the increasing prevalence of RA. Kevzara helps manage RA symptoms by blocking IL-6, a protein responsible for driving inflammation, which helps reduce inflammation, improve joint health, and enhance the quality of life for affected individuals. For example, in June 2024, the Australian Institute of Health and Welfare reported that around 514,000 people in Australia (2% of the population) were living with RA in 2022, resulting in 1,322 deaths, and 10,000 hospitalizations due to RA in 2021-2022. As the prevalence of RA continues to rise, it is driving the growth of the kevzara market.

The increase in healthcare expenditure is expected to propel the growth of the kevzara market. Healthcare expenditure refers to the total financial resources allocated for health services and products within a region. Several factors, including an aging population, advances in medical technology, rising healthcare prices, and an emphasis on preventive care, contribute to the rise in healthcare spending. Kevzara, being an expensive biologic treatment for rheumatoid arthritis and other inflammatory conditions, requires long-term administration, resulting in substantial treatment costs. These costs significantly contribute to overall healthcare expenditure for both patients and healthcare systems. For instance, according to the Office for National Statistics, total healthcare expenditure in the UK rose by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. This increase in healthcare spending is driving the growth of the kevzara market.

A key trend in the kevzara market is the development of advanced therapies such as interleukin-6 (IL-6) receptor blockers to expand the treatment options for inflammatory disorders. IL-6 receptor blockers are biological drugs that target and block IL-6, a protein that drives inflammation. By reducing inflammation, these treatments help manage conditions such as rheumatoid arthritis. In February 2023, Regeneron Pharmaceuticals and Sanofi announced that the U.S. Food and Drug Administration (FDA) had approved Kevzara (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic condition. This approval provides an alternative treatment for PMR patients who have not responded well to corticosteroids or cannot tolerate reductions in their steroid dosage. Kevzara has shown significant efficacy in reducing inflammation and achieving sustained remission in PMR patients, further expanding its therapeutic applications. This advancement is contributing to the growth of the kevzara market.

Major companies operating in the kevzara market are Sanofi S.A. and Regeneron Pharmaceuticals Inc.

North America was the largest region in the kevzara market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in kevzara report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the kevzara market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Kevzara is a prescription biologic medication classified as a monoclonal antibody, specifically designed to treat moderate to severe rheumatoid arthritis (RA) in adults. It works by targeting and inhibiting interleukin-6 (IL-6), a protein involved in inflammation. By blocking IL-6 receptors, Kevzara helps reduce inflammation and alleviate symptoms associated with RA. Additionally, Kevzara may be prescribed for other inflammatory conditions as directed by healthcare professionals.

The primary formulations of kevzara include injectable formulations and autoinjectors. Injectable formulations deliver biological therapies directly into the bloodstream via injection, ensuring controlled release and effective treatment for chronic conditions such as rheumatoid arthritis. Kevzara is used for various indications, such as treating moderate to severe rheumatoid arthritis, giant cell arteritis, and other conditions, and is suitable for different patient demographics, including pediatric, adult, and geriatric patients. It is distributed through several channels, such as direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies, and is used in various settings, including hospitals, specialty clinics, outpatient treatment centers, and home healthcare providers.

The kevzara market research report is one of a series of new reports that provides kevzara market statistics, including the kevzara industry global market size, regional shares, competitors with the kevzara market share, detailed kevzara market segments, market trends, and opportunities, and any further data you may need to thrive in the kevzara industry. This kevzara market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The kevzara market consists of sales of subcutaneous injections, pre-filled syringes, and pre-filled pens. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.